

Thrombosis in paroxysmal nocturnal hemoglobinuria

Blood

121, 4985-4996

DOI: [10.1182/blood-2012-09-311381](https://doi.org/10.1182/blood-2012-09-311381)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Review: The Guitar and its Music: From the Renaissance to the Classical Era. Music and Letters, 2004, 85, 424-427.	0.0	0
3	Learnings from over 25 years of PNH experience: The era of targeted complement inhibition. Blood Reviews, 2013, 27, S1-S6.	2.8	5
4	Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. Clinical Biochemistry, 2013, 46, 1798-1803.	0.8	19
5	Complement activation in diseases presenting with thrombotic microangiopathy. European Journal of Internal Medicine, 2013, 24, 496-502.	1.0	78
6	GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. Orphanet Journal of Rare Diseases, 2013, 8, 170.	1.2	13
7	Blood consult: paroxysmal nocturnal hemoglobinuria and its complications. Blood, 2013, 122, 2795-2798.	0.6	7
8	TMA: beware of complements. Blood, 2013, 122, 1997-1999.	0.6	21
9	Paroxysmal nocturnal hemoglobinuria. Hematologie, 2013, 19, 319-330.	0.0	3
10	An unusual case of epigastric pain. BMJ, The, 2014, 348, g3689-g3689.	3.0	1
11	Paroxysmal Nocturnal Hemoglobinuria. , 2014, , 1462-1470.		1
12	Extracellular Vesicles in Hematological Disorders. Rambam Maimonides Medical Journal, 2014, 5, e0032.	0.4	26
13	Recurrent life-threatening reactions to platelet transfusion in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone. Internal Medicine Journal, 2014, 44, 925-927.	0.5	0
14	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 2014, 7, 583-598.	1.0	43
15	The Role of Decay Accelerating Factor in Environmentally Induced and Idiopathic Systemic Autoimmune Disease. Autoimmune Diseases, 2014, 2014, 1-12.	2.7	12
16	Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. Thrombosis Research, 2014, 133, 1052-1055.	0.8	17
17	Rapidly evolving skin manifestations due to progressive thrombosis in a patient with paroxysmal nocturnal haemoglobinuria resolved with prompt initiation of eculizumab. British Journal of Dermatology, 2014, 171, 908-910.	1.4	2
18	Thrombotic Microangiopathies and the Linkage between von Willebrand Factor and the Alternative Complement Pathway. Seminars in Thrombosis and Hemostasis, 2014, 40, 544-550.	1.5	46
19	Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatric Blood and Cancer, 2014, 61, 1544-1550.	0.8	35

#	ARTICLE	IF	CITATIONS
20	Paroxysmal nocturnal hemoglobinuria: a single Spanish center's experience over the last 40Âyr. <i>European Journal of Haematology</i> , 2014, 93, 309-319.	1.1	29
22	Paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2014, 124, 2804-2811.	0.6	424
23	How I treat splanchnic vein thrombosis. <i>Blood</i> , 2014, 124, 3685-3691.	0.6	71
24	Complement in hemolytic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 385-391.	0.9	9
26	Hemoglobin interaction with GP1bÂ induces platelet activation and apoptosis: a novel mechanism associated with intravascular hemolysis. <i>Haematologica</i> , 2015, 100, 1526-1533.	1.7	42
27	Complement in hemolytic anemia. <i>Blood</i> , 2015, 126, 2459-2465.	0.6	84
28	Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. <i>Blood</i> , 2015, 125, 3253-3262.	0.6	151
29	A patient with paroxysmal nocturnal hemoglobinuria being treated with eculizumab who underwent laparoscopic cholecystectomy: report of a case. <i>Surgical Case Reports</i> , 2015, 1, 57.	0.2	5
30	Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2004-2011.	1.9	23
31	Severe thrombophilias. , 0, , 166-179.		0
32	New Insights in Abdominal Pain in Paroxysmal Nocturnal Hemoglobinuria (PNH): A MRI Study. <i>PLoS ONE</i> , 2015, 10, e0122832.	1.1	8
33	Long standing eculizumab treatment without anticoagulant therapy in high-risk thrombogenic paroxysmal nocturnal hemoglobinuria. <i>Hematology Reports</i> , 2015, 7, 5927.	0.3	5
34	Role of Complement and Complement Regulatory Proteins in the Complications of Diabetes. <i>Endocrine Reviews</i> , 2015, 36, 272-288.	8.9	127
35	Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. <i>European Journal of Haematology</i> , 2015, 95, 190-198.	1.1	85
36	Early-onset chronic axonal neuropathy, strokes, and hemolysis. <i>Neurology</i> , 2015, 84, 1220-1224.	1.5	40
37	BuddâChiari syndrome. <i>United European Gastroenterology Journal</i> , 2015, 3, 489-500.	1.6	72
38	Platelet microparticle: A sensitive physiological âœfine tuningâ balancing factor in health and disease. <i>Transfusion and Apheresis Science</i> , 2015, 52, 12-18.	0.5	54
39	Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab. <i>Thrombosis Research</i> , 2015, 136, 274-281.	0.8	10

#	ARTICLE	IF	CITATIONS
40	Paroxysmal Nocturnal Hemoglobinuria in Pregnancy. , 2015, , 327-342.		1
41	Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology, 2015, 160, 237-243.	1.4	42
42	Venous thromboembolism related to warm autoimmune hemolytic anemia: A caseâ€“control study. Autoimmunity Reviews, 2015, 14, 1023-1028.	2.5	43
44	Paroxysmal Nocturnal Hemoglobinuria. Hematology/Oncology Clinics of North America, 2015, 29, 479-494.	0.9	52
45	An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort. Hematology, 2015, 20, 31-38.	0.7	12
46	Congenital CD59 Deficiency. Hematology/Oncology Clinics of North America, 2015, 29, 495-507.	0.9	11
47	Paroxysmal nocturnal hemoglobinuria revisited: news on pathophysiology, clinical course and treatment. Laboratoriums Medizin, 2015, 39, 87-96.	0.1	0
48	Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease. European Journal of Haematology, 2015, 94, 464-473.	1.1	27
49	Cerebral Venous Thrombosis in Paroxysmal Nocturnal Hemoglobinuria. Medicine (United States), 2015, 94, e362.	0.4	30
50	Paroxysmal nocturnal haemoglobinuria: to prednisone or not to prednisone? â€“ a case report of a patient previously treated with steroids for 15Âyrs and significant response on eculizumab. European Journal of Haematology, 2015, 95, 177-180.	1.1	3
52	New perspectives on the thrombotic complications of haemolysis. British Journal of Haematology, 2015, 168, 175-185.	1.2	58
53	Successful use of eculizumab for treatment of an acute hemolytic reaction after <sc>ABO</sc>â€“incompatible red blood cell transfusion. Transfusion, 2015, 55, 605-610.	0.8	27
54	Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Translational Research, 2015, 165, 306-320.	2.2	64
55	Positive predictive value of diagnosis coding for hemolytic anemias in the Danish National Patient Register. Clinical Epidemiology, 2016, Volume 8, 241-252.	1.5	14
56	Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. Journal of Korean Medical Science, 2016, 31, 214.	1.1	51
57	Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria. F1000Research, 2016, 5, 209.	0.8	38
58	Positive Impact of Eculizumab Therapy on Surgery for Budd- Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Longterm History of Thrombosis. Hematology Reports, 2016, 8, 34-36.	0.3	4
59	Acute Myocardial Infarction Caused by Thrombotic Microangiopathy Complicated With Myelodysplastic Syndrome. International Heart Journal, 2016, 57, 634-636.	0.5	9

#	ARTICLE	IF	CITATIONS
60	Inhibition of Hb Binding to GP1b± Abrogates Hb-Mediated Thrombus Formation on Immobilized VWF and Collagen under Physiological Shear Stress. PLoS ONE, 2016, 11, e0154276.	1.1	6
61	Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation. Xenotransplantation, 2016, 23, 117-127.	1.6	10
62	Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology American Society of Hematology Education Program, 2016, 2016, 208-216.	0.9	85
63	Anemia aplásica. Hemoglobinuria paroxística nocturna. Medicina, 2016, 12, 1159-1169.	0.0	0
64	Examining coagulation-complement crosstalk: complement activation and thrombosis. Thrombosis Research, 2016, 141, S50-S54.	0.8	57
65	Cross Talk Pathways Between Coagulation and Inflammation. Circulation Research, 2016, 118, 1392-1408.	2.0	418
66	Are there any additional mechanisms for haemolysis in HELLP syndrome?. Thrombosis Research, 2016, 142, 40-43.	0.8	10
67	Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Medicina Clínica (English Edition), 2016, 146, 278.e1-278.e7.	0.1	7
68	PEGylated Artificial Antibodies: Plasmonic Biosensors with Improved Selectivity. ACS Applied Materials & Interfaces, 2016, 8, 23509-23516.	4.0	40
69	Neurologic Manifestations of Blood Dyscrasias. Hematology/Oncology Clinics of North America, 2016, 30, 723-731.	0.9	10
70	Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Annals of Neurology, 2016, 80, 708-717.	2.8	41
71	The dysfunction of platelets in paroxysmal nocturnal hemoglobinuria. Thrombosis Research, 2016, 148, 50-55.	0.8	5
72	Self-€nonself discrimination by the complement system. FEBS Letters, 2016, 590, 2418-2434.	1.3	66
73	Protection of host cells by complement regulators. Immunological Reviews, 2016, 274, 152-171.	2.8	173
74	Characteristics of Taiwanese patients of PNH in the international PNH registry. Thrombosis Journal, 2016, 14, 39.	0.9	4
75	Purpura fulminans related to paroxysmal nocturnal haemoglobinuria. European Journal of Dermatology, 2016, 26, 397-398.	0.3	4
76	Disseminated intravascular coagulation € new pathophysiological concepts and impact on management. Expert Review of Hematology, 2016, 9, 803-814.	1.0	39
77	A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. International Journal of Hematology, 2016, 103, 649-654.	0.7	26

#	ARTICLE	IF	CITATIONS
78	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. American Journal of Hematology, 2016, 91, 366-370.	2.0	110
80	Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 383-391.	0.3	5
81	Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. Annals of Hematology, 2016, 95, 125-133.	0.8	14
82	An Algorithmic Approach to Management of Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 511-517.	0.7	1
83	Paroxysmal Nocturnal Hemoglobinuria. , 2017, , .		1
84	Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood, 2017, 129, 2291-2302.	0.6	188
85	Complementopathies. Blood Reviews, 2017, 31, 213-223.	2.8	86
86	Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. Therapeutic Advances in Hematology, 2017, 8, 119-126.	1.1	40
87	HUS and atypical HUS. Blood, 2017, 129, 2847-2856.	0.6	218
88	How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood, 2017, 129, 3285-3293.	0.6	39
89	Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis. Expert Opinion on Orphan Drugs, 2017, 5, 375-379.	0.5	1
90	Complement: A primer for the coming therapeutic revolution. , 2017, 172, 63-72.		67
91	Demyelination, strokes, and eculizumab: Lessons from the congenital CD59 gene mutations. Molecular Immunology, 2017, 89, 69-72.	1.0	19
92	Paroxysmal nocturnal haemoglobinuria. Nature Reviews Disease Primers, 2017, 3, 17028.	18.1	299
93	Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thrombosis Research, 2017, 156, 142-148.	0.8	7
94	Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Internal Medicine Journal, 2017, 47, 1026-1034.	0.5	19
95	Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. Blood Cells, Molecules, and Diseases, 2017, 65, 29-34.	0.6	20
96	Circulating Extracellular DNA: Cause or Consequence of Thrombosis?. Seminars in Thrombosis and Hemostasis, 2017, 43, 553-561.	1.5	59

#	ARTICLE	IF	CITATIONS
98	A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 64, 45-50.	0.6	11
99	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. <i>Blood</i> , 2017, 129, 970-980.	0.6	119
100	Development of pro-inflammatory phenotype in monocytes after engulfing Hb-activated platelets in hemolytic disorders. <i>Clinical Immunology</i> , 2017, 175, 133-142.	1.4	12
101	After the Party's Over. <i>New England Journal of Medicine</i> , 2017, 376, 74-80.	13.9	16
102	Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. <i>Haematologica</i> , 2017, 102, e76-e79.	1.7	15
103	Red blood cells in thrombosis. <i>Blood</i> , 2017, 130, 1795-1799.	0.6	228
104	Paroxysmal nocturnal haemoglobinuria diagnosis in a woman after foetal loss. <i>International Journal of Laboratory Hematology</i> , 2017, 39, e86-e89.	0.7	0
105	Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab. <i>Medicine (United States)</i> , 2017, 96, e6403.	0.4	6
106	Multiple Lacunar Infarcts in Paroxysmal Nocturnal Hemoglobinuria. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, e199-e202.	0.7	7
107	60-Year-Old Woman With Headache and Fatigue. <i>Mayo Clinic Proceedings</i> , 2017, 92, e121-e125.	1.4	2
108	Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 361-370.	0.7	19
109	Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 311-317.	1.2	14
110	Microvesicles in vascular homeostasis and diseases. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1296-1316.	1.8	193
111	Diffuse Venous Thrombosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1871-1872.	1.4	0
112	Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 2525-2532.	0.8	1
113	Paroxysmal Nocturnal Hemoglobinuria in Pregnancy: A Dilemma in Treatment and Thromboprophylaxis. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.3	5
114	Cerebral Stroke in a Teenage Girl with Paroxysmal Nocturnal Hemoglobinuria. <i>Hematology Reports</i> , 2017, 9, 7012.	0.3	2
115	Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease. <i>Seminars in Hematology</i> , 2018, 55, 141-149.	1.8	50

#	ARTICLE	IF	CITATIONS
116	Thrombophilic States. , 2018, , 325-343.		0
117	Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria. <i>Seminars in Hematology</i> , 2018, 55, 124-129.	1.8	19
118	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. <i>Seminars in Hematology</i> , 2018, 55, 167-175.	1.8	32
119	Complement links platelets to innate immunity. <i>Seminars in Immunology</i> , 2018, 37, 43-52.	2.7	45
120	Haemostasis and innate immunity â€” a complementary relationship. <i>British Journal of Haematology</i> , 2018, 180, 782-798.	1.2	120
121	The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. <i>Haematologica</i> , 2018, 103, 9-17.	1.7	35
122	Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymptomatic Patients. <i>Scientific Reports</i> , 2018, 8, 476.	1.6	8
123	Diseases of complement dysregulationâ€”an overview. <i>Seminars in Immunopathology</i> , 2018, 40, 49-64.	2.8	83
124	Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor. <i>Seminars in Hematology</i> , 2018, 55, 136-140.	1.8	16
125	Bleeding and Thrombosis in Hematologic Neoplasia. , 2018, , 1263-1289.		1
126	Eculizumab treatment for ischemic enteritis accompanied with paroxysmal nocturnal hemoglobinuria: a case report and literature review. <i>Annals of Hematology</i> , 2018, 97, 1513-1515.	0.8	1
127	Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e9-e12.	0.2	1
128	Nephrotic-range proteinuria and brown urine in an 8-year-old girl: Questions. <i>Pediatric Nephrology</i> , 2018, 33, 1001-1002.	0.9	0
129	Nephrotic-range proteinuria and brown urine in an 8-year-old girl: Answers. <i>Pediatric Nephrology</i> , 2018, 33, 1003-1005.	0.9	0
130	ICCS/ESCCA Consensus Guidelines to detect GPIâ€”deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 1 â€” Clinical Utility. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 16-22.	0.7	37
131	The Mutual Relation of Platelet Activation and Innate Immunity. <i>Hamostaseologie</i> , 2018, 38, 186-202.	0.9	11
132	Anticoagulating patients with high-risk acquired thrombophilias. <i>Blood</i> , 2018, 132, 2219-2229.	0.6	13
133	Venous thromboembolic events during warm autoimmune hemolytic anemia. <i>PLoS ONE</i> , 2018, 13, e0207218.	1.1	49

#	ARTICLE	IF	CITATIONS
134	Rare thrombophilic conditions. <i>Annals of Translational Medicine</i> , 2018, 6, 342-342.	0.7	13
135	Renal involvement in paroxysmal nocturnal haemoglobinuria: a brief review of the literature. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 1139-1146.	0.3	5
136	A Case of Glaucoma in Hereditary Spherocytosis. <i>Journal of Glaucoma</i> , 2018, 27, e187-e190.	0.8	0
137	Nonimmune Hemolytic Anemia. , 2018, , 294-313.		0
138	Inter-laboratory validation of a harmonized PNH flow cytometry assay. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 736-743.	0.7	4
139	The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Scientific Reports</i> , 2018, 8, 13458.	1.6	3
140	Fibrin Clot Structure and Function. , 2018, , 31-49.		1
141	Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. <i>European Journal of Haematology</i> , 2018, 101, 737-749.	1.1	27
142	Autoimmune hemolytic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 382-389.	0.9	93
143	Anticoagulating patients with high-risk acquired thrombophilias. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 439-449.	0.9	5
144	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. <i>Blood Advances</i> , 2018, 2, 2176-2185.	2.5	65
145	Prothrombotic mechanisms in patients with congenital p.Cys89Tyr mutation in CD59. <i>Thrombosis Research</i> , 2018, 168, 67-77.	0.8	9
146	Paroxysmal Nocturnal Hemoglobinuria. , 2018, , 415-424.		1
147	Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases. <i>FEBS Journal</i> , 2019, 286, 826-854.	2.2	125
148	Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1639.	2.2	17
149	Prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. <i>Annals of Hematology</i> , 2019, 98, 2283-2291.	0.8	4
150	Paroxysmal Nocturnal Hemoglobinuria: Diagnostic Challenges in Pediatric Patient. <i>Case Reports in Pediatrics</i> , 2019, 2019, 1-5.	0.2	2
151	Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. <i>International Journal of Hematology</i> , 2019, 110, 411-418.	0.7	9

#	ARTICLE	IF	CITATIONS
152	Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. <i>Frontiers in Immunology</i> , 2019, 10, 1157.	2.2	133
153	First exploratory study on the metabolome from plasma exosomes in patients with paroxysmal nocturnal hemoglobinuria. <i>Thrombosis Research</i> , 2019, 183, 80-85.	0.8	12
154	Mechanisms of haemolysis-induced kidney injury. <i>Nature Reviews Nephrology</i> , 2019, 15, 671-692.	4.1	97
156	Extensive purpura as presenting sign of parvovirus B19 infection in a patient with paroxysmal nocturnal hemoglobinuria. <i>JAAD Case Reports</i> , 2019, 5, 798-800.	0.4	1
157	Novel insights into the treatment of complement-mediated hemolytic anemias. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987332.	1.1	65
158	Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 175-179.	0.2	0
159	Red Blood Cell Homeostasis and Altered Vesicle Formation in Patients With Paroxysmal Nocturnal Hemoglobinuria. <i>Frontiers in Physiology</i> , 2019, 10, 578.	1.3	9
160	Deep vein thrombosis: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019, 210, 516-524.	0.8	73
161	Absence of Nonclassical Monocytes in Hemolytic Patients: Free Hb and NO-Mediated Mechanism. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	0.9	3
162	Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Case Reports in Hematology</i> , 2019, 2019, 1-5.	0.3	1
163	Differential miRNA expression profile and proteome in plasma exosomes from patients with paroxysmal nocturnal hemoglobinuria. <i>Scientific Reports</i> , 2019, 9, 3611.	1.6	13
164	Gene mutations associated with thrombosis detected by whole-exome sequencing in paroxysmal nocturnal hemoglobinuria. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 424-432.	0.7	6
165	The Extended Use of Eculizumab in Pregnancy and Complement Activation—Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now?. <i>Journal of Clinical Medicine</i> , 2019, 8, 407.	1.0	25
166	Le urgenze ematologiche. <i>Italian Journal of Medicine</i> , 2019, , 1-100.	0.2	0
167	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2019, 71, 175-199.	1.8	80
169	C1 inhibitor in canine intravascular hemolysis (C1INCH): study protocol for a randomized controlled trial. <i>BMC Veterinary Research</i> , 2019, 15, 475.	0.7	1
170	Severity of Anaemia Has Corresponding Effects on Coagulation Parameters of Sickle Cell Disease Patients. <i>Diseases (Basel, Switzerland)</i> , 2019, 7, 59.	1.0	3
171	CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann's disease. <i>Immunological Reviews</i> , 2019, 287, 20-32.	2.8	18

#	ARTICLE	IF	CITATIONS
172	Venous thromboembolism prophylaxis using the Caprini score. <i>Disease-a-Month</i> , 2019, 65, 249-298.	0.4	68
173	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. <i>Blood</i> , 2019, 133, 540-549.	0.6	239
174	How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. <i>European Journal of Haematology</i> , 2019, 102, 36-52.	1.1	41
175	Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2019, 104, e94-e96.	1.7	14
176	Complement-Mediated Coagulation Disorders. , 2019, , 473-490.		0
178	Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23008.	0.9	14
179	Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. <i>Leukemia and Lymphoma</i> , 2020, 61, 1242-1245.	0.6	1
180	Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 318-329.	1.0	5
181	Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results from a multicentre cross-sectional study. <i>Thrombosis Research</i> , 2020, 185, 85-87.	0.8	0
182	Presence of paroxysmal nocturnal hemoglobinuria in patients with idiopathic portal vein thrombosis: a single-center study. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1344-1349.	0.4	2
183	Is the COVID-19 thrombotic catastrophe complement-connected?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2812-2822.	1.9	53
184	Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report. <i>HemaSphere</i> , 2020, 4, e455.	1.2	4
185	Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 341-348.	0.1	14
186	Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102538.	0.9	32
188	Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network. <i>Annals of Hematology</i> , 2020, 99, 2303-2313.	0.8	5
189	Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1535-1547.	1.9	31
190	Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. <i>Journal of Clinical Medicine</i> , 2020, 9, 1261.	1.0	5
191	Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. <i>Annals of Hematology</i> , 2020, 99, 1505-1514.	0.8	63

#	ARTICLE	IF	CITATIONS
192	FLAERâ€negative CD15+ neutrophils can be used for the simplified screening of suspected PNH cases. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 589-593.	0.7	1
193	Hemoglobinâ€bound platelets correlate with the increased platelet activity in hemoglobin E/ β^0 â€thalassemia. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 518-525.	0.7	2
194	An interesting case of atypical venous thrombosis with low red blood cells. <i>Italian Journal of Medicine</i> , 2020, 14, 22-26.	0.2	1
195	Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry. <i>Practical Laboratory Medicine</i> , 2020, 20, e00158.	0.6	10
196	PNH phenotypes and their genesis. <i>British Journal of Haematology</i> , 2020, 189, 802-805.	1.2	7
197	Congenital Hemolytic Anemias: Is There a Role for the Immune System?. <i>Frontiers in Immunology</i> , 2020, 11, 1309.	2.2	19
198	Thrombotic disorders (part 2). <i>South African Medical Journal</i> , 2020, 110, 181.	0.2	0
199	Complement in Hemolysis- and Thrombosis- Related Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 1212.	2.2	40
200	Paroxysmal Nocturnal Hemoglobinuria: An Underestimated Cause of Pediatric Thromboembolism. <i>TH Open</i> , 2020, 04, e36-e39.	0.7	0
201	New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. <i>Frontiers in Immunology</i> , 2020, 11, 590.	2.2	85
202	Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. <i>American Journal of Hematology</i> , 2020, 95, 944-952.	2.0	3
203	Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype. <i>Clinical Hemorheology and Microcirculation</i> , 2020, , 1-13.	0.9	1
204	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2020, 106, 230-237.	1.7	77
205	Editor's Choice â€“ European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 9-82.	0.8	308
206	Advances in Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 301-307.	0.6	4
207	Upper gastrointestinal ischemia as a rare complication of paroxysmal nocturnal hemoglobinuria. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 506-510.	0.2	0
209	Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices. <i>American Journal of Medicine</i> , 2021, 134, e147-e149.	0.6	0
210	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 607-616.	1.9	45

#	ARTICLE	IF	CITATIONS
211	Paroxysmal Nocturnal Hemoglobinuria: Case Report of a Rare Cause of Thrombosis in the Pediatric Age. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e240-e242.	0.3	0
212	Circulating extracellular vesicles and cytokines in congenital and acquired hemolytic anemias. <i>American Journal of Hematology</i> , 2021, 96, E129-E132.	2.0	4
213	How I treat paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2021, 137, 1304-1309.	0.6	63
214	Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. <i>Journal of Clinical Medicine</i> , 2021, 10, 948.	1.0	7
215	Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria. <i>Blood Cancer Journal</i> , 2021, 11, 58.	2.8	4
216	Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. <i>Pharmacological Reviews</i> , 2021, 73, 792-827.	7.1	97
217	JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature. <i>Thrombosis Journal</i> , 2021, 19, 16.	0.9	5
219	It takes two to thrombosis: Hemolysis and complement. <i>Blood Reviews</i> , 2021, 50, 100834.	2.8	19
220	Thrombotic Complications in Patients with Immune-Mediated Hemolysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1764.	1.0	14
221	A Rare and Misdiagnosed Entity Paroxysmal Nocturnal Hemoglobinuria: A Case Report. <i>Cureus</i> , 2021, 13, e14902.	0.2	2
222	Circulating Endothelial Progenitor Cells and Their Relation to Thrombosis in Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 319-326.	0.3	0
223	Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience. <i>Annals of Hematology</i> , 2021, 100, 1667-1675.	0.8	0
225	Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2188.	1.0	15
226	Complement, inflammation and thrombosis. <i>British Journal of Pharmacology</i> , 2021, 178, 2892-2904.	2.7	39
227	Complement and the prothrombotic state. <i>Blood</i> , 2022, 139, 1954-1972.	0.6	15
228	How we (â€™) treat paroxysmal nocturnal haemoglobinuria: diving into the future. <i>British Journal of Haematology</i> , 2022, 196, 288-303.	1.2	27
229	Myasthenia gravis and paroxysmal nocturnal hemoglobinuria after thymectomy: A rare association. <i>EJHaem</i> , 0, , .	0.4	0
230	Coexistence of Primary Myelofibrosis and Paroxysmal Nocturnal Hemoglobinuria Clone with JAK2 V617F, U2AF1 and SETBP1 Mutations: A Case Report and Brief Review of Literature. <i>Diagnostics</i> , 2021, 11, 1644.	1.3	1

#	ARTICLE	IF	CITATIONS
231	Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study. European Journal of Haematology, 2022, 108, 45-51.	1.1	9
232	Cost-Utility Analysis of Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria From the Perspective of the Brazilian Public Health System. Value in Health Regional Issues, 2021, 26, 113-125.	0.5	0
233	Thrombosis and paroxysmal nocturnal haemoglobinuria. Thrombosis Update, 2021, 5, 100074.	0.4	1
234	Understanding therapeutic emergencies in acute hemolysis. Intensive Care Medicine, 2018, 44, 482-485.	3.9	3
235	Recurrent cerebral ischaemic events in the setting of paroxysmal nocturnal haemoglobinuria. BMJ Case Reports, 2016, 2016, bcr2015213603.	0.2	3
236	Complementopathies and precision medicine. Journal of Clinical Investigation, 2020, 130, 2152-2163.	3.9	70
237	Blood Cell Disorders and the Nervous System. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 659-674.	0.4	2
238	Polymorphism of the <i>ABO</i> gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. Oncotarget, 2017, 8, 92411-92419.	0.8	7
239	Extracellular Vesicles from Red Blood Cells and Their Evolving Roles in Health, Coagulopathy and Therapy. International Journal of Molecular Sciences, 2021, 22, 153.	1.8	77
241	Endovideosurgeries in the setting of haematological diseases. Endoscopic Surgery, 2014, 20, 46.	0.0	0
243	Complement and Complement Regulatory Proteins in Diabetes. , 2015, , 29-57.		1
244	A case of classic paroxysmal nocturnal hemoglobinuria. International Journal of Case Reports and Images, 2015, 6, 370.	0.0	1
245	Paroxysmal Nocturnal Hemoglobinuria: Report Of Suboptimal Response To The Use Of Eculizumab. International Archive of Medicine, 0, , .	1.2	0
247	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	0.9	0
248	Thrombophilia in PNH. , 2017, , 153-172.		0
249	Clinical Effects of Eculizumab in PNH. , 2017, , 271-282.		0
250	Clinical Management in PNH. , 2017, , 253-269.		0
251	A History of Research of PNH: Defining a Disease. , 2017, , 1-8.		0

#	ARTICLE	IF	CITATIONS
252	Haemolysis in PNH: Depletion of Nitric Oxide. , 2017, , 121-135.		0
253	Paroxysmal nocturnal hemoglobinuria case presenting as cerebral venous sinus thrombosis. Journal of Surgery and Medicine, 0, , .	0.0	0
254	Paroxysmal nocturnal hemoglobinuria. Vnitrni Lekarstvi, 2018, 64, 508-513.	0.1	0
255	Disorders of the Human Circulatory System. Advances in Bioinformatics and Biomedical Engineering Book Series, 2019, , 288-324.	0.2	0
257	Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia: Challenges, Characteristics, and Analysis of Clinical Experience. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 319-328.	0.1	3
258	Paroxysmal Nocturnal Hemoglobinuria Presenting with Chronic Abdominal Pain and Iron Deficiency Anemia. Korean Journal of Medicine, 2020, 95, 56-60.	0.1	0
259	Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. Journal of Managed Care & Specialty Pharmacy, 2020, 26, S14-S20.	0.5	8
260	Post-PE Management. Respiratory Medicine, 2020, , 153-180.	0.1	0
261	COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. American Journal of the Medical Sciences, 2022, 363, 465-475.	0.4	16
262	Eculizumab in the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 193-199.	0.1	0
263	Biotechnological products for the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria: currently available and in development. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 164-172.	0.1	0
264	Is Allogeneic Stem Cell Transplantation a Good Option for Paroxysmal Nocturnal Haemoglobinuria?. European Medical Journal Hematology, 0, , .	0.0	0
265	Anemias por fallo medular. Anemia aplásica adquirida. Hemoglobinuria paroxística nocturna. Medicine, 2020, 13, 1178-1190.	0.0	0
266	Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. American Journal of Blood Research, 2015, 5, 1-9.	0.6	22
267	PNH is a debilitating, fatal but treatable disease: same disease, different clinical presentations. American Journal of Blood Research, 2015, 5, 30-3.	0.6	3
268	Pesg PNH diagnosis, follow-up and treatment guidelines. American Journal of Blood Research, 2016, 6, 19-27.	0.6	14
272	Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis. American Journal of Blood Research, 2021, 11, 279-285.	0.6	0
273	A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. American Journal of Hematology, 2022, 97, .	2.0	6

#	ARTICLE	IF	CITATIONS
274	Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 756589.	1.3	2
275	Primary Immunodeficiencies and Non Malignant Hematologic Disease Associated with Disorders of Hepatic Vessels. , 2022, , 311-328.		0
276	Complement-related thrombosis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 695-707.	0.1	0
278	Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. <i>European Journal of Haematology</i> , 2022, 108, 391-402.	1.1	4
279	Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study. <i>Hematology</i> , 2022, 27, 113-121.	0.7	2
280	Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 84.	0.1	0
281	Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 113.	0.4	3
282	Pegcetacoplan for paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2022, 139, 3361-3365.	0.6	6
283	Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: <scp>Realâ€world</scp> findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>European Journal of Haematology</i> , 2022, 109, 197-204.	1.1	3
284	Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?. <i>British Journal of Haematology</i> , 2022, 196, 264-265.	1.2	7
285	O, wind, if winter comes â€ will symptoms be far behind?. <i>Transfusion</i> , 2022, 62, 2-10.	0.8	6
286	When does a PNH clone have clinical significance?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 143-152.	0.9	9
287	Management of Vascular Thrombosis in Patients with Thrombocytopenia. <i>Hamostaseologie</i> , 2022, 42, 019-028.	0.9	0
294	Longâ€term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2â€year results from two pivotal phase 3 studies. <i>European Journal of Haematology</i> , 2022, 109, 205-214.	1.1	19
296	The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210910.	1.1	10
297	Thrombophilia testing: A British Society for Haematology guideline. <i>British Journal of Haematology</i> , 2022, 198, 443-458.	1.2	29
298	An unusual postoperative manifestation of paroxysmal nocturnal haemoglobinuria following gender reâ€affirming mastectomy. <i>ANZ Journal of Surgery</i> , 0, , .	0.3	0
299	Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective. <i>Journal of Blood Medicine</i> , 0, Volume 13, 327-335.	0.7	6

#	ARTICLE	IF	CITATIONS
300	The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life. <i>European Journal of Haematology</i> , 2022, 109, 351-363.	1.1	10
301	Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls. <i>Seminars in Immunology</i> , 2022, 59, 101618.	2.7	9
302	Vasculitic Moyamoya syndrome in a patient with paroxysmal nocturnal hemoglobinuria: A case report and literature review. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 1464-1468.	1.9	2
303	The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 969-985.	0.6	5
304	Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. <i>New England Journal of Medicine</i> , 2022, 387, 160-166.	13.9	28
305	Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. <i>Annals of Hematology</i> , 2022, 101, 1905-1914.	0.8	7
306	The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 851-861.	1.3	4
307	Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria. <i>Seminars in Hematology</i> , 2022, 59, 143-149.	1.8	4
308	Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia. <i>Thrombosis Journal</i> , 2022, 20, .	0.9	7
309	Portal vein thrombosis as the first presentation of paroxysmal nocturnal hemoglobinuria. <i>Drug Discoveries and Therapeutics</i> , 2022, 16, 200-203.	0.6	1
310	The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective. <i>Hematology</i> , 2022, 27, 1140-1151.	0.7	3
311	Subacute stent thrombosis with spontaneously resolved secondary thrombi in paroxysmal nocturnal hemoglobinuria: a case report. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	0
312	The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. <i>Immunological Reviews</i> , 2023, 313, 262-278.	2.8	9
313	Tissue factor in COVID-19-associated coagulopathy. <i>Thrombosis Research</i> , 2022, 220, 35-47.	0.8	16
314	Detection of paroxysmal nocturnal haemoglobinuria clones in cases of deep vein thrombosis in a tertiary care centre, western Rajasthan. <i>Indian Journal of Medical Research</i> , 2022, .	0.4	0
315	Hemolytic anemia and thrombosis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2022, 33, 580-582.	0.1	0
316	Red blood cells contribution in blood coagulation. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2022, 21, 136-141.	0.1	0
317	Clinical guidelines for the management of patients with paroxysmal nocturnal hemoglobinuria. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 426-439.	0.1	3

#	ARTICLE	IF	CITATIONS
318	A CASE REPORT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. , 2022, , 3-4.		0
319	Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis. Journal of the Royal College of Physicians of Edinburgh, The, 2022, 52, 341-349.	0.2	1
320	Genome-wide analyses of early-onset acute myocardial infarction identify 29 novel loci by whole genome sequencing. Human Genetics, 2023, 142, 231-243.	1.8	1
321	Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multiâ€protein cascade of the complement system. Immunological Reviews, 2023, 313, 376-401.	2.8	6
322	Thrombosis in Pregnant Women with Hemolytic Anemia. Seminars in Thrombosis and Hemostasis, 0, , .	1.5	1
323	Paroxysmal nocturnal hemoglobinuria with sagittal vein thrombosis as the initial presentation. International Journal of Case Reports and Images, 2022, 13, 205-209.	0.0	0
324	Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. Blood Reviews, 2023, 59, 101041.	2.8	3
325	Paroxysmal nocturnal hemoglobinuria: Where we stand. American Journal of Hematology, 2023, 98, .	2.0	3
326	Thrombosis in Haematological Disorders: Tailored Management Approaches. European Medical Journal Hematology, 0, , 38-46.	0.0	0
327	Hypercoagulable states associated with chronic venous insufficiency. , 2023, , 139-157.		0
328	Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes. European Journal of Haematology, 2023, 110, 648-658.	1.1	1
329	CD59: Biological function and its potential for drug target action. Gene Reports, 2023, 31, 101772.	0.4	0
330	Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study. Frontiers in Oncology, 0, 13, .	1.3	2
331	Cardiac Arrest Secondary to Inferior ST-Segment-Elevation Myocardial Infarction in Patient with Paroxysmal Nocturnal Hemoglobinuria and COVID-19 Infection. Cureus, 2023, , .	0.2	0
332	Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH. Journal of Blood Medicine, 0, Volume 14, 239-245.	0.7	1
333	Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France. Journal of Comparative Effectiveness Research, 2023, 12, .	0.6	0
334	Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations. Advances in Therapy, 0, , .	1.3	2
354	Rare Thrombophilic Disorder. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
358	Case report: a case of paroxysmal nocturnal hemoglobinuria with ischemic stroke as the first symptom. , 0, , .		0
359	Multisite thrombosis in a patient with paroxysmal nocturnal hemoglobinuria. Hamostaseologie, 2024, , .	0.9	0